Journal
DRUG DELIVERY
Volume 27, Issue 1, Pages 607-621Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2020.1754529
Keywords
Astragalus polysaccharides; targeting ER alpha-positive breast cancer; multidrug resistance; nano-pomegranates
Categories
Funding
- Taishan Young Scholar Program [qnts20161035]
- Shandong Provincial Natural Science Foundation [ZR2019ZD24, ZR2019YQ30]
- Open fund project of State Key Laboratory of Bio-Fibers and Eco-Textile (Qingdao University) [K2019-21]
Ask authors/readers for more resources
Chemotherapy is an important method for treating breast cancer. However, multidrug resistance is one of the major challenges in breast cancer chemotherapy. There is an urgent need to develop novel, effective antitumor strategies that will perfect existing therapeutic regimens. In this study, the double-targeted nanocarrier, Quercetin-3'3-dithiodipropionic acid-Astragalus polysaccharides-Folic acid (QDAF), was successfully synthesized and self-assembled into a neoteric nano-targeted delivery strategy, named nano-pomegranates, and which were utilized to effectively inhibit multidrug resistance in estrogen receptor alpha (ER alpha)-positive breast tumor. The outstanding abilities of nano-pomegranates to release the drug in a reducing environment was determined by in vitro release assay. The cellular studies in MCF-7 cells were examined that nano-pomegranates have remarkable efficiencies of enhancing cellular uptake, inhibition and necrosis and apoptosis. In vivo antitumor experiments showed that nano-pomegranates have better anti-tumor effects and lower systemic toxicity than free Cur. In conclusion, nano-pomegranates have great potential in anti-breast cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available